A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

NCT04108156 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

634

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
DRUG: Intravitreal Ranibizumab 0.5 mg Injection
DRUG: Ranibizumab refill exchange

Sponsor

Hoffmann-La Roche